Scalper1 News
BioMarin Pharmaceutical (BMRN) and Intercept Pharmaceuticals (ICPT) stocks were heading in opposite directions after both of their closely-watched drugs received delays in their FDA approval decisions. BioMarin’s Duchenne muscular dystrophy (DMD) treatment Kyndrisa (drisapersen) had a decision deadline, or PDUFA date, of Dec. 27, which meant that the news was widely expected to come by Christmas Eve. However, BioMarin said in a brief statement Scalper1 News
Scalper1 News